Newsletters

[Blood] By screening the nucleoporin (NUP) family, scientists identified NUP214 as a frequently overexpressed gene and a critical fitness determinant in leukemia stem cells (LSCs). NUP214 acts as a conserved driver of LSC survival by restricting heme catabolism, limiting Fe²⁺ accumulation, and suppressing lipid peroxidation.

[Leukemia] Researchers identified the RNA splicing factor PTBP1 as a key dependency in acute myeloid leukemia, sustaining leukemia by controlling the processing of essential oncogenic transcripts.

[Leukemia] Investigators mapped purinergic signaling at single-cell resolution in human cord blood stem and progenitor cells, revealing how ATP and adenosine pathways are organized across early blood cell development.

[British Journal of Haematology] The authors investigated the expression of CD39, CD73 and related adenosinergic pathways and their clinical associations in T cells of higher-risk myelodysplastic syndromes patients undergoing hypomethylating agent therapy.

[Blood Advances] Scientists showed that chemotherapy-induced anemia is driven by Caspase-1–mediated ROCK1 activation, which suppresses red blood cell production and reveals a potential therapeutic target for improving erythropoietic recovery.

[Blood] Researchers assessed whether DNA methylation patterns in AML patients can augment risk assessments provided by genetic and other markers to better predict outcomes

[British Journal of Pharmacology] The authors discuss the rationale and evidence for combining histone deacetylase inhibitors with venetoclax in AML, including mechanisms of action, resistance pathways, and preclinical and clinical data

[PharmaEssentia USA Corporation (Business Wire)] PharmaEssentia USA Corporation announced the US FDA has approved BESREMi^® for the treatment of adults with essential thrombocythemia (ET), making it the first new FDA-approved treatment for ET in nearly three decades.

[University of Cincinnati] The University of Cincinnati Cancer Center’s Dr. Sarah Skuli, has received a two-year, $150,000 New Investigator Research Grant from the Leukemia Research Foundation. The funds will go toward a project that focuses on leukemia carrying mutations in the TP53 gene, which leads to very poor outcomes for patients.

[Biotechnology Advances] Successful macrophage immunotherapy requires solving two central in vivo determinants: preserving a therapeutically favorable functional state despite suppressive cues, and achieving robust, disease-selective localization and engagement.

[Blood] Investigators identified immunosenescence as a measurable and functionally consequential barrier to CAR T-cell efficacy in chronic lymphocytic leukemia and a candidate for therapeutic modulation.

[Leukemia] Researcher showed that CAR structure is a critical determinant of CD19 loss in tumor B cells. Specifically, repeated exposure to CD19–4-1BB-based CAR-T cells, but not CD19–CD28-based counterparts, drives FMC63-epitope and total CD19 protein loss.